Search

Your search keyword '"Boher, J"' showing total 151 results

Search Constraints

Start Over You searched for: Author "Boher, J" Remove constraint Author: "Boher, J"
151 results on '"Boher, J"'

Search Results

2. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

3. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer

6. S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSUS HLA-MATCHED UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS

17. Erratum: Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

23. Benefit of adjuvant systemic therapies in HR+ HER2- pT1ab node-negative breast carcinomas

24. Impact of hormone receptor status in HER2+ early breast cancer: A paradigm shift in the trastuzumab era

25. Abstract P3-01-02: Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: Axillary dissection versus no axillary dissection in patients with involved sentinel node

26. Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approach

27. The Choice of Effectiveness Criteria Affects Conclusions of Economic Evaluation of Health Care Innovations: Example Based on A Randomised Multicenter Trial Comparing Two Reduced Intensity Conditioning Regimen (FLU-BU-ATG) Vs. (FLU-TBI) For Matched Related Allogeneic Stem Cells Transplantation

28. French Intensive Care Society, International congress - Réanimation 2016

32. Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

38. Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial

39. How to report toxicity associated with targeted therapies?

40. Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT

41. Allogeneic Stem Cell Transplantation from Matched Related Donor in Patients Over the Age of 55 Years After Reduced Intensity Conditioning Associating Fludarabine-Iv Busulfan and Rabbit-Antithymocyte Globulin: A Prospective Multicenter Phase II Clinical Trial with Socio Economic Evaluation

42. P4-20-01: Multicentric Phase II PACS 09/Beverly1 Trial: First Efficacy and Safety Results of Neoadjuvant Chemotherapy Combined with Bevacizumab in HER2−Negative Patients with Non-Metastatic Inflammatory Breast Cancer.

45. Post-Operative 5FU-Docetaxel after High-Dose of Pre-Operative Epirubicin-Cyclophosphamide for Treatment of Inflammatory Breast Cancer: Results of the FNCLCC-Pegase 07 Trial.

Catalog

Books, media, physical & digital resources